CSIMarket
 
Oncorus Inc   (NASDAQ: ONCR)
Other Ticker:  
 
 
Price: $0.1260 $0.00 -3.077%
Day's High: $0.2 Week Perf: 869.23 %
Day's Low: $ 0.13 30 Day Perf: 193.02 %
Volume (M): 136 52 Wk High: $ 0.00
Volume (M$): $ 17 52 Wk Avg: $0.00
Open: $0.13 52 Wk Low: $0.00



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 26
 Employees 34
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 18

Oncorus Inc
Oncorus Inc is a biotechnology company dedicated to the development of innovative immunotherapies for the treatment of various types of cancers. The company focuses on developing viral-based therapies that can selectively infect and destroy cancer cells while leaving healthy cells intact. Oncorus uses a proprietary therapeutic platform called Synthetic Virus, which enables the design and production of potent viral vectors for therapeutic purposes. These viral vectors can deliver therapeutic payloads directly to cancer cells, enhancing the immune response and potentially improving patient outcomes. The company's mission is to improve the lives of cancer patients and advance the field of immuno-oncology through their innovative approaches.


   Company Address: 4 Corporate Drive Andover 1810 MA
   Company Phone Number: 320-6400   Stock Exchange / Ticker: NASDAQ ONCR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.06% 
ICPT        0.21% 
INVA   -1.09%    
PFE   -0.48%    
SUPN        2.94% 
VRTX   -1.44%    
• View Complete Report
   



Vertex Pharmaceuticals Inc

Decrease in Income at the Vertex Pharmaceuticals Inc during the fiscal fourth quarter of 2024

Vertex Pharmaceuticals Incs' income deteriorated, regardless of Revenue growth in the October to December 31 2024, income decreased by -4.11 % to $3.55 per share, while Revenue increased admirably by 15.661 % to $2.91 billion, from the comparable financial reporting period a year prior. VRTXs' revenue, surge in the fourth quarter of 2024 correlates positively to its Major Pharmaceutical Preparations sector peers, which experienced overall 5.46 % top-line growth in the same period yet.

Johnson And Johnson

Earnings deteriorated while revenue grew in the fourth quarter of 2024 earnings season

The Major Pharmaceutical Preparations company delivered contradictory numbers in the fiscal fourth quarter of 2024, where Revenue grew by 5.258 % to $22.52 billion in comparison to $21.40 billion on a year-over-year basis, while income fell by -15.26 % to $1.43 per share, off $1.68 in the prior year financial reporting period. Yet the JNJs' business increase trailing theMajor Pharmaceutical Preparations sector contemporaries, had an average 5.46% compared to the comparable period a year before business elevation.

Rezolute Inc

Between many corporations, the RZLT disclosed also its second quarter of 2025 numbers

The Major Pharmaceutical Preparations sector observers start to interpret the second quarter of 2025 results. Now those observers observe operating deficit of $-17.08 million, from the Rezolute Inc , which hasn't stated any revenue thus far, for the respective October to December 31 2024 reporting period.

Aytu Biopharma Inc

Earnings lifted by $0.28 million tax benefit

Weak business caused rise in losses for the second quarter of 2025 financial report, company's net loss per share inched up to $-0.26 from $-0.04 where Revenue went down by -28.901 % to $15.79 million from $22.20 million a year before. The remainder ofMajor Pharmaceutical Preparations sector, posted a top-line improvement in the second quarter of 2025.

Alkermes Plc

Strong Eps Underlines Double Digits revenue rise at in the October to December 31 2024 interval

Shifting our awareness towards the fourth quarter of 2024 financial report profit per share went up by 42.83 % to $0.90 per share, followed by Revenue boost of 13.911 % to $429.99 million, compared with the prior year period. Major Pharmaceutical Preparations company's business grew more compared to the the revenue at almost all of the Major Pharmaceutical Preparations sector contemporaries, in the fourth quarter of 2024 the most corporations in Major Pharmaceutical Preparations sectors had the business rise of 5.46% from the same reporting season a year ago.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com